Lably
Skip to content

Bifikafusp alfa/onfekafusp alfa

Combination medication

  • 1 min read
  • 1 chapter

Related on Lably

Through Protein

Lab · Class 11–12Biomolecules of LifeLab · Class 11Biomolecules — Animated Chapter FilmLab · Class 11Locomotion and Movement — Animated Chapter FilmLab · Class 4–6Food and Nutrition

Bifikafusp alfa consists of interleukin-2 (IL-2), a naturally occurring protein that activates certain white blood cells that can recognize and attack cancer cells. Bifikafusp alfa is linked to L19, another protein which was expected to enable the medicine to target cancer cells and not healthy tissue. Onfekafusp alfa consists of tumor necrosis factor which disrupts the blood supply to the tumor, and is also linked to L19.

In June 2025, Philogen S.p.A. withdrew its application in the European Union for a marketing authorization of Nidlegy for the treatment of melanoma, a type of skin cancer.

More in Health

Food and Drug AdministrationFederal agency of the United States Department of Health and Human ServicesCenters for Disease Control and PreventionUnited States government public health agencyNauseaMedical symptom or conditionSeizurePeriod of symptoms due to excessive or synchronous neuronal brain activityVomitingExpulsion of stomach contents via the mouth or noseIntravenous therapyMedication administered into a vein